X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

June 27, 2019

Industry Trends in Biologic Formulations

In 2018, we saw a record-setting year for new-molecular entity (NME) approvals (59) at the FDA1 versus 46 in 2017. 58% were for orphan drugs (patient population less than 200,000 in the US) with 17 biologic-based NME’s. Biosimilars are gaining traction in Europe, in particular. Major factors that are driving the market growth are next-generation business, high growth in chronic diseases, less expensive biosimilar drugs and favorable government regulations.
Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts
    Elastomers

    June 25, 2019

    Bromobutyl versus Chlorobutyl Rubber Formulations - General Aspects

    Heike Kofler

    Dr. Heike Kofler

    Manager, Technical Customer Support Europe

    Canine Partners for Life

    June 06, 2019

    West in the Community: Canine Partners for Life

    Marisa Leuzzi

    Marisa Leuzzi

    Senior Specialist, Corporate Communications

    SmartDose In-Use

    May 07, 2019

    The Impact Poor Formulations Have on Drug Development Programs

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics

    Load more